化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症临床研究  

Clinical Study on Huazhuo Tongluo Dingxuan Decoction Combined with Western Medicine for Vertigo of Phlegm and Blood Stasis Obstructing Orifices Type

作　　者：章元 李靖 庄荣河 ZHANG Yuan;LI Jing;ZHUANG Ronghe(Department of Neurosurgery,People's Hospital of Wuxing District of Huzhou/Huzhou Maternity&Child Health Care Hospital,Huzhou Zhejiang 313000,China)

机构地区：[1]湖州市吴兴区人民医院/湖州市吴兴区妇幼保健院神经外科,浙江湖州313000

出　　处：《新中医》2025年第5期64-68,共5页New Chinese Medicine

摘　　要：目的:观察化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症的临床疗效。方法:选择2020年6月—2023年6月湖州市吴兴区人民医院/湖州市吴兴区妇幼保健院收治的80例痰瘀阻窍型眩晕症患者,按随机数字表法分为治疗组和对照组各40例。对照组给予倍他司汀、盐酸异丙嗪治疗,治疗组在对照组基础上加用化浊通络定眩汤治疗,2组均治疗14 d。比较2组治疗前后中医证候积分、眩晕症状评定量表(DARS)评分、脑部(基底、左椎、右椎)动脉血流速度、红细胞聚集指数、全血高切黏度、血浆黏度、内皮素-1(ET-1)、降钙素基因相关肽(CGRP)水平,并评估2组临床疗效及不良反应发生情况。结果:治疗后,治疗组总有效率95.00%(38/40),高于对照组77.50%(31/40),差异有统计学意义(P<0.05)。治疗后,2组脑部基底、左椎、右椎动脉血流速度及CGRP水平均较治疗前升高(P<0.05),DARS评分、中医证候积分、红细胞聚集指数、全血高切黏度、血浆黏度及ET-1水平降低(P<0.05);治疗组各脑部动脉血流速度及CGRP水平高于对照组(P<0.05),DARS评分、中医证候积分、红细胞聚集指数、全血高切黏度、血浆黏度及ET-1水平低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症,能提高患者脑部血流速度,改善血液高凝状态,减轻眩晕症状,临床疗效显著,安全性较高。Objective:To observe the clinical effect of Huazhuo Tongluo Dingxuan Decoction combined with western medicine on vertigo of phlegm and blood stasis obstructing orifices type.Methods:A total of 80 cases of patients with vertigo of phlegm and blood stasis obstructing orifices type,treated in People's Hospital of Wuxing District of Huzhou/Huzhou Maternity&Child Health Care Hospital from June 2020 to June 2023,were selected and divided into the treatment group and the control group according to the random number table method,with 40 cases in each group.The control group was treated with Betahistine and Promethazine Hydrochloride,and the treatment group was additionally treated with Huazhuo Tongluo Dingxuan Decoction based on the treatment of the control group.Both groups were treated for 14 days.The traditional Chinese medicine(TCM)syndrome scores,Dizziness Assessment Rating Scale(DARS)scores,cerebral(basilar,left vertebral,right vertebral)artery blood flow velocity,erythrocyte aggregation index,whole blood high-shear viscosity,plasma viscosity,endothelin-1(ET-1),and calcitonin gene related peptide(CGRP)levels in the two groups were compared before and after treatment.Clinical effects and adverse reactions in the two groups were also evaluated.Results:After treatment,the total effective rate was 95.00%(38/40)in the treatment group,higher than that of 77.50%(31/40)in the control group,with a significant difference(P<0.05).After treatment,both groups showed increased cerebral artery blood flow velocity(basilar,left vertebral,right vertebral)and CGRP levels compared to before treatment(P<0.05),and DARS scores,TCM syndrome scores,erythrocyte aggregation indexes,whole blood high-shear viscosity,plasma viscosity,and ET-1 levels were decreased(P<0.05).The treatment group had higher cerebral artery blood flow velocity and CGRP level than the control group(P<0.05),and lower DARS score,TCM syndrome score,erythrocyte aggregation index,whole blood high-shear viscosity,plasma viscosity,and ET-1 level than the control group(P<0.05

关 键 词：眩晕症 化浊通络定眩汤 脑部血流速度 内皮素-1 降钙素基因相关肽 

分 类 号：R255.3[医药卫生—中医内科学]